Filing Flows › BridgeBio Pharma (BBIO) › Q3 2025
BridgeBio Pharma (BBIO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 29, 2025
BridgeBio Pharma (BBIO) reported revenue of $121M for the third quarter 2025 (Q3 2025), up 44-fold from a year earlier and +9% from the quarter before. Operating margin was -120.3%, net loss $185M (153.2% of revenue).
BridgeBio Pharma, Q3 2025: revenue $121M (44× year over year), operating margin -120.3%, net loss $185M, operating cash flow −$110M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121M | +9% | 44× |
| Operating profit | −$145M | — | — |
| Net earnings | −$185M | — | — |
| Operating cash flow | −$110M | — | — |
What changed
Revenue was $120.7M in Q3 2025, up 4318% year over year and up 9% from the previous quarter. Net product revenue was the largest line at 90% of revenue. License and services revenue added $5.6M year over year (up 204%), 5% of the total change.
Operating costs exceeded revenue by $145.2M, an operating margin of -120.3%. Total costs grew 37% against revenue growth of 4318%. The fastest-growing cost line was Cost of revenue (+997%). The quarter ended with a net loss of $184.9M, wider than the previous quarter's $183.8M loss. Minority interests bore $2.2M of it: to shareholders the quarter was a loss of $182.7M.
Operating cash flow was −$109.6M. Non-cash charges added back $1.4M of depreciation and amortization and $35.3M of share-based compensation. Working capital and other items added $38.7M. Capital expenditures of $470K exceeded it, leaving free cash flow of −$110.0M.
Questions
What was BridgeBio Pharma's revenue in the third quarter 2025?
BridgeBio Pharma (BBIO) reported revenue of $121M for the third quarter 2025 (Q3 2025), up 44-fold from a year earlier and +9% from the quarter before.
Was BridgeBio Pharma profitable in the third quarter 2025?
Operating loss was $145M (-120.3% of revenue) and net loss $185M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.